Transgenic drosophilia melanogaster expressing beta amyloid
CA 2423613 A1 · Owner: Finelli, Alyce Lynn · Inventors: Finelli, Alyce Lynn; Dengler, Uwe Jochen; Reinhardt, Mischa Werner Henri Marie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Transgenic files displaying altered phenotypes due to expression of the Abeta and C99 portions of the human APP gene are disclosed. Use of these files in a method to identify Drosophila genes and the human homologs of these Drosophila genes, that are potentially involved in Alzheimer's Disease is also , disclosed. The use of said human homologs as drug targets for the development of therapeutics to treat Alzheimer's Disease and other conditions associated with defects in the APP pathway, as well as pharmaceutical compositions comprising substances directed to these genes are also disclosed.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 1, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 1, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 1, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.